Dentsply Sirona (XRAY) appooints new board members
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Canaccord Genuity Reiterates Buy Rating on Globus Medical (GMED)
February 6, 2025 1:25 PM ESTCanaccord Genuity analyst William J. Plovanic reiterated a Buy rating and $101.00 price target on Globus Medical (NYSE: GMED).
The analyst comments "Our take: We believe that this acquisition is further evidence of GMED continuing to go on the offensive even as it integrates its sizable acquisition of NUVA. With over one year since the NUVA merger, we are impressed by the progress GMED has achieved and how it's remained... More
Needham Reiterates Hold Rating on Globus Medical (GMED)
February 6, 2025 12:43 PM ESTNeedham analyst Mike Matson reiterated a Hold rating on Globus Medical (NYSE: GMED).
The analyst comments "This morning, GMED announced an agreement to acquire Nevro (NVRO, Not Rated) for $5.85 per share in cash, or an enterprise value of ~$195M. NVRO provides the HFX... More
Jefferies Reiterates Buy Rating on Globus Medical (GMED)
February 6, 2025 12:19 PM ESTJefferies analyst Matthew Taylor reiterated a Buy rating and $105.00 price target on Globus Medical (NYSE: GMED)
The analyst comments "On 2.6.25, GMED announced plans to acquire NVRO (UNPF) for ~$250MM in equity value ~0.6x sales. Assuming a 2Q25 close, GMED forecasts ~20c in... More
BTIG on Globus Medical (GMED) Buying NVRO: 'The Market May Not Like It'
February 6, 2025 11:32 AM ESTBTIG analyst Ryan Zimmerman reiterated a Buy rating and $91.00 price target on Globus Medical (NYSE: GMED).
The analyst comments "This morning, GMED announced a definitive agreement to acquire Nevro Corp (NVRO, Not Rated) for ~$250M or ~0.6x EV/FY25 sales. Yes, this is surprising on the surface. We don't believe investors expected that GMED would move into... More
